Welcome to LookChem.com Sign In|Join Free
  • or
2-BROMO-3'-HYDROXYACETOPHENONE is an organic compound with the molecular formula C8H7BrO2. It is a white solid that serves as a key intermediate in the synthesis of various pharmaceutical compounds and organic molecules. Its chemical structure features a bromo group at the 2nd position and a hydroxy group at the 3' position, attached to an acetophenone backbone.

2491-37-4

Post Buying Request

2491-37-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2491-37-4 Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-3'-HYDROXYACETOPHENONE is used as a reactant for the synthesis of various pharmaceutical compounds, including:
1. Pyrrole-3-carboxylic acids: These are important building blocks in the development of novel drugs with potential applications in treating various diseases.
2. N-aryl-N-thiazolyl compounds: Synthesized through the Hantzsch reaction, these compounds exhibit a wide range of biological activities, such as anti-inflammatory, analgesic, and nitric oxide releasing properties.
3. Disubstituted oxadiazolylindole derivatives: These compounds possess anti-inflammatory, analgesic, and nitric oxide releasing activities, making them valuable in the development of new medications for pain relief and inflammation management.
4. Anilino-aryl-thiazoles: These compounds exhibit inhibitory activity towards valosin-containing proteins, which play a crucial role in cellular protein folding and are implicated in various diseases. Inhibitors of these proteins can be used for therapeutic purposes.
5. Tyrosine kinase erythropoietin inhibitors: These inhibitors are essential in the treatment of anemia and other blood-related disorders by modulating the activity of erythropoietin, a hormone that stimulates red blood cell production.
6. E. coli methionine aminopeptidase inhibitors: These inhibitors are used in the development of new antibiotics targeting bacterial enzymes, potentially leading to more effective treatments for bacterial infections.

Check Digit Verification of cas no

The CAS Registry Mumber 2491-37-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,4,9 and 1 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2491-37:
(6*2)+(5*4)+(4*9)+(3*1)+(2*3)+(1*7)=84
84 % 10 = 4
So 2491-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H7BrO2/c9-5-8(11)6-2-1-3-7(10)4-6/h1-4,10H,5H2

2491-37-4Synthetic route

3-Hydroxyacetophenone
121-71-1

3-Hydroxyacetophenone

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
With aluminium trichloride; Montmorillonite K10; bromine In ethyl acetate at 20℃; for 2h;89%
With copper(I) bromide In chloroform; ethyl acetate for 0.333333h; Sonication;80%
With dioxane dibromide In 1,4-dioxane; tert-butyl methyl ether63%
3-(bromoethynyl)phenol
1370031-23-4

3-(bromoethynyl)phenol

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
With cerium(IV) sulphate; sulfuric acid; water In dichloromethane at 80℃; for 12h; Sealed tube; regioselective reaction;89%
With indium(III) triflate; water In acetic acid at 100℃; Sealed tube;82%
3-(t-butoxy)acetophenone
99376-84-8

3-(t-butoxy)acetophenone

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
With bromine In chloroform81%
2-bromo-3'-methoxyacetophenone
5000-65-7

2-bromo-3'-methoxyacetophenone

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
Stage #1: 2-bromo-3'-methoxyacetophenone With boron tribromide In dichloromethane at -10℃; for 1.5h;
Stage #2: With water In dichloromethane at 0℃;
24%
With boron tribromide In dichloromethane1.3 g (69%)
With boron tribromide In dichloromethane1.3 g (69%)
3-acetylphenyl acetate
2454-35-5

3-acetylphenyl acetate

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: bromine; aluminum (III) chloride / diethyl ether / -10 °C
2: sodium hydrogencarbonate / methanol
View Scheme
2-bromo-3-acetyloxylacetophenone
38396-89-3

2-bromo-3-acetyloxylacetophenone

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
With sodium hydrogencarbonate In methanol
1-(tert-butoxycarbonyl)-L-proline
15761-39-4

1-(tert-butoxycarbonyl)-L-proline

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

1-(tert-butyl) 2-(2-(3-hydroxyphenyl)-2-oxoethyl) (S)-pyrrolidine-1,2-dicarboxylate

1-(tert-butyl) 2-(2-(3-hydroxyphenyl)-2-oxoethyl) (S)-pyrrolidine-1,2-dicarboxylate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 5h;91%
With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 5h;91%
With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 5h;91%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

N-(2-fluorophenyl)thiourea
656-32-6

N-(2-fluorophenyl)thiourea

3-(2-((2-fluorophenyl)amino)thiazol-4-yl)phenol

3-(2-((2-fluorophenyl)amino)thiazol-4-yl)phenol

Conditions
ConditionsYield
In ethanol at 80℃; for 2h; Sealed tube;91%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol
23766-28-1

5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol

2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)-1-(3-hydroxyphenyl)ethanone

2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
Stage #1: 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol With triethylamine In ethanol for 0.25h;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol for 3h; Reflux;
89%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-Mercapto-5-phenyl-1,3,4-oxadiazole
3004-42-0

2-Mercapto-5-phenyl-1,3,4-oxadiazole

1-(3-hydroxyphenyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-ethanone

1-(3-hydroxyphenyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-ethanone

Conditions
ConditionsYield
Stage #1: 2-Mercapto-5-phenyl-1,3,4-oxadiazole With triethylamine In ethanol for 0.25h;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol for 3h; Reflux;
89%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-(1-(pyridin-2-yl)ethylidene)hydrazinecarbothioamide

2-(1-(pyridin-2-yl)ethylidene)hydrazinecarbothioamide

3-(2-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

3-(2-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

Conditions
ConditionsYield
With triethylamine In ethanol for 3h; Hantzsch Thiazole Synthesis; Reflux;89%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-(1-(pyridin-4-yl)ethylidene)hydrazinecarbothioamide
3115-21-7

2-(1-(pyridin-4-yl)ethylidene)hydrazinecarbothioamide

3-(2-(2-(1-(pyridin-4-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

3-(2-(2-(1-(pyridin-4-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

Conditions
ConditionsYield
With triethylamine In ethanol for 3h; Hantzsch Thiazole Synthesis; Reflux;89%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-[1-(pyridine-3-yl)ethylidene]hydrazinecarbothioamide
13370-86-0

2-[1-(pyridine-3-yl)ethylidene]hydrazinecarbothioamide

3-(2-(2-(1-(pyridin-3-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

3-(2-(2-(1-(pyridin-3-yl)ethylidene)hydrazinyl)thiazol-4-yl)phenol

Conditions
ConditionsYield
With triethylamine In ethanol for 3h; Hantzsch Thiazole Synthesis; Reflux;89%
pyridine-3-carbaldehyde thiosemicarbazone
555-90-8

pyridine-3-carbaldehyde thiosemicarbazone

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

3-(2-(2-(pyridin-3-ylmethylene)hydrazinyl)thiazol-4-yl)phenol

3-(2-(2-(pyridin-3-ylmethylene)hydrazinyl)thiazol-4-yl)phenol

Conditions
ConditionsYield
With triethylamine In ethanol for 3h; Hantzsch Thiazole Synthesis; Reflux;89%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

5-(3-pyridinyl)-1,3,4-oxadiazol-2-thiol
3690-46-8

5-(3-pyridinyl)-1,3,4-oxadiazol-2-thiol

1-(3-hydroxyphenyl)-2-{[5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-1-ethanone

1-(3-hydroxyphenyl)-2-{[5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-1-ethanone

Conditions
ConditionsYield
Stage #1: 5-(3-pyridinyl)-1,3,4-oxadiazol-2-thiol With triethylamine In ethanol for 0.25h;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol for 3h; Reflux;
88%
5-(4-benzyloxy-phenyl)-[1,3,4]oxadiazole-2-thiol
741262-94-2

5-(4-benzyloxy-phenyl)-[1,3,4]oxadiazole-2-thiol

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-({5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2-yl}sulfanyl)-1-(3-hydroxyphenyl)-1-ethanone

2-({5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2-yl}sulfanyl)-1-(3-hydroxyphenyl)-1-ethanone

Conditions
ConditionsYield
Stage #1: 5-(4-benzyloxy-phenyl)-[1,3,4]oxadiazole-2-thiol With triethylamine In ethanol for 0.25h;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol for 3h; Reflux;
87%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2,5-Dimercapto-1,3,4-thiadiazole
1072-71-5

2,5-Dimercapto-1,3,4-thiadiazole

2,20-(1,3,4-thiadiazole-2,5-diyl)bis(sulfanediyl)bis(1-(3-hydroxyphenyl)ethanone)

2,20-(1,3,4-thiadiazole-2,5-diyl)bis(sulfanediyl)bis(1-(3-hydroxyphenyl)ethanone)

Conditions
ConditionsYield
Stage #1: 2,5-Dimercapto-1,3,4-thiadiazole With triethylamine In ethanol for 0.25h;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol for 3h; Reflux;
87%
(E)-2-(2,3-dihydro-1H-inden-1-ylidene)hydrazine-1-carbothioamide

(E)-2-(2,3-dihydro-1H-inden-1-ylidene)hydrazine-1-carbothioamide

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

(E)-3-(2-(2-(2, 3-dihydro-1H-inden-1-ylidene)hydrazinyl)thiazol-4-yl)phenol

(E)-3-(2-(2-(2, 3-dihydro-1H-inden-1-ylidene)hydrazinyl)thiazol-4-yl)phenol

Conditions
ConditionsYield
In ethanol for 4h; Hantzsch Thiazole Synthesis; Reflux;86%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

thioacetamide
62-55-5

thioacetamide

3-(2-methylthiazol-4-yl)phenol

3-(2-methylthiazol-4-yl)phenol

Conditions
ConditionsYield
In ethanol for 2h; Reflux; Inert atmosphere;85%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

5-(quinoxalin-3-yl)-4H-1,2,4-triazole-3-thiol

5-(quinoxalin-3-yl)-4H-1,2,4-triazole-3-thiol

3-(3-(quinoxalin-2-yl)thiazolo[2,3-c][1,2,4]triazol-5-yl)phenol

3-(3-(quinoxalin-2-yl)thiazolo[2,3-c][1,2,4]triazol-5-yl)phenol

Conditions
ConditionsYield
for 12h; Reflux;85%
pyridine-2-carbothioamide
5346-38-3

pyridine-2-carbothioamide

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

3-[2-(pyridin-2-yl)thiazol-4-yl]phenol

3-[2-(pyridin-2-yl)thiazol-4-yl]phenol

Conditions
ConditionsYield
Stage #1: pyridine-2-carbothioamide; 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol at 20℃; for 0.5h;
Stage #2: In ethanol for 1h; Reflux;
82%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

allyl bromide
106-95-6

allyl bromide

3-(1-bromo-2-hydroxypent-4-en-2-yl)phenol
1450629-59-0

3-(1-bromo-2-hydroxypent-4-en-2-yl)phenol

Conditions
ConditionsYield
With indium In tetrahydrofuran; water at 20℃;81%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

pyridine-4-carbothioamide
2196-13-6

pyridine-4-carbothioamide

3-[2-(pyridin-4-yl)thiazol-4-yl]phenol

3-[2-(pyridin-4-yl)thiazol-4-yl]phenol

Conditions
ConditionsYield
Stage #1: 2-bromo-1-(3-hydroxyphenyl)ethanone; pyridine-4-carbothioamide In ethanol at 20℃; for 0.5h;
Stage #2: In ethanol for 1h; Reflux;
80%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

pyrimidine-2-carbothioamide
4537-73-9

pyrimidine-2-carbothioamide

4-(3-hydroxyphenyl)-2-(pyrimidine-2-yl)thiazole

4-(3-hydroxyphenyl)-2-(pyrimidine-2-yl)thiazole

Conditions
ConditionsYield
In ethanol at 20 - 78℃;80%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

5-bromo-2-amino-1,3,4-thiadiazole
37566-39-5

5-bromo-2-amino-1,3,4-thiadiazole

3-(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-6-yl)phenol
1391927-80-2

3-(2-bromoimidazo[2,1-b][1,3,4]thiadiazol-6-yl)phenol

Conditions
ConditionsYield
In ethanol for 12h; Reflux;78%
thionicotinamide
4621-66-3

thionicotinamide

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

3-[2-(pyridin-3-yl)thiazol-4-yl]phenol

3-[2-(pyridin-3-yl)thiazol-4-yl]phenol

Conditions
ConditionsYield
Stage #1: thionicotinamide; 2-bromo-1-(3-hydroxyphenyl)ethanone In ethanol at 20℃; for 0.5h;
Stage #2: In ethanol for 1h; Reflux;
78%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

pyrrolidinodithiocarboxylic acid, pyrrolidinium salt
6962-31-8

pyrrolidinodithiocarboxylic acid, pyrrolidinium salt

1-(3'-hydroxyphenyl)-2-(pyrrolidin-1-ylthiocarbonylthio)-1-ethanone

1-(3'-hydroxyphenyl)-2-(pyrrolidin-1-ylthiocarbonylthio)-1-ethanone

Conditions
ConditionsYield
In water; acetone for 0.166667h; Heating;76%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

3-methyl-8-bromoxanthine
93703-24-3

3-methyl-8-bromoxanthine

8-bromo-3,7-dihydro-7-[2-(3-hydroxyphenyl)-2-oxoethyl]-3-methyl-1H-purine-2,6-dione
1192215-80-7

8-bromo-3,7-dihydro-7-[2-(3-hydroxyphenyl)-2-oxoethyl]-3-methyl-1H-purine-2,6-dione

Conditions
ConditionsYield
Stage #1: 3-methyl-8-bromoxanthine With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃; for 0.0833333h; Inert atmosphere;
Stage #2: 2-bromo-1-(3-hydroxyphenyl)ethanone In N,N-dimethyl-formamide at 25℃; Inert atmosphere;
75%
(Z)-2-(2-oxoindolin-3-ylidene)-hydrazinecarbothioamide
487-16-1, 26134-45-2, 27830-79-1, 1165809-20-0

(Z)-2-(2-oxoindolin-3-ylidene)-hydrazinecarbothioamide

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

(Z)-3-(2-(4-(3-hydroxyphenyl)thiazol-2-yl)hydrazono)indolin-2-one

(Z)-3-(2-(4-(3-hydroxyphenyl)thiazol-2-yl)hydrazono)indolin-2-one

Conditions
ConditionsYield
In ethanol for 4h; Hantzsch Thiazole Synthesis; Reflux;75%
2-amino-benzthiazole
136-95-8

2-amino-benzthiazole

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-(m-hydroxyphenyl)imidazo<2,1-b>benzothiazole
79889-39-7

2-(m-hydroxyphenyl)imidazo<2,1-b>benzothiazole

Conditions
ConditionsYield
In isopropyl alcohol for 2h; Heating;70%
2,5-dihydro-3H-1,2,4-triazino[5,6-b]indole-3-thione
28668-95-3

2,5-dihydro-3H-1,2,4-triazino[5,6-b]indole-3-thione

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-1-(3-hydroxyphenyl)ethanone

2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-1-(3-hydroxyphenyl)ethanone

Conditions
ConditionsYield
With triethylamine In ethanol for 3h; Reflux;70%
2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

(3-methylsulfanylphenyl)thiourea

(3-methylsulfanylphenyl)thiourea

3-(2-((3-(methylthio)phenyl)amino)thiazol-4-yl)phenol

3-(2-((3-(methylthio)phenyl)amino)thiazol-4-yl)phenol

Conditions
ConditionsYield
In ethanol Hantzsch Thiazole Synthesis; Reflux;69%
t-butyl 3-amino-2-(N-benzoylthiocarbamoyl)crotonate
84362-13-0

t-butyl 3-amino-2-(N-benzoylthiocarbamoyl)crotonate

2-bromo-1-(3-hydroxyphenyl)ethanone
2491-37-4

2-bromo-1-(3-hydroxyphenyl)ethanone

t-butyl 2-benzamido-5-m-hydroxybenzoyl-4-methyl-3-thenoate

t-butyl 2-benzamido-5-m-hydroxybenzoyl-4-methyl-3-thenoate

Conditions
ConditionsYield
65%

2491-37-4Relevant academic research and scientific papers

Structure-Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity

Varghese, Swapna,Rahmani, Rapha?l,Drew, Damien R.,Beeson, James G.,Baum, Jake,Smith, Brian J.,Baell, Jonathan B.

, p. 679 - 693 (2020/11/30)

Malarial parasites employ actin dynamics for motility, and any disruption to these dynamics renders the parasites unable to effectively establish infection. Therefore, actin presents a potential target for malarial drug discovery, and naturally occurring actin inhibitors such as latrunculins are a promising starting point. However, the limited availability of the natural product and the laborious route for synthesis of latrunculins have hindered their potential development as drug candidates. In this regard, we recently described novel truncated latrunculins, with superior actin binding potency and selectivity towards P. falciparum actin than the canonical latrunculin B. In this paper, we further explore the truncated latrunculin core to summarize the SAR for inhibition of malaria motility. This study helps further understand the binding pattern of these analogues in order to develop them as drug candidates for malaria.

Nucleus-independent chemical shift (NICS) as a criterion for the design of new antifungal benzofuranones

González-Chávez, Marco Martín,González-Chávez, Rodolfo,Méndez, Francisco,Martínez, Roberto,Ni?o-Moreno, Perla Del Carmen,Ojeda-Fuentes, Luis Enrique,Richaud, Arlette,Zerme?o-Macías, María de los ángeles

, (2021/08/30)

The assertion made by Wu et al. that aromaticity may have considerable implications for molecular design motivated us to use nucleus-independent chemical shifts (NICS) as an aromaticity criterion to evaluate the antifungal activity of two series of indol-4-ones. A linear regression analysis of NICS and antifungal activity showed that both tested variables were significantly related (p –1 for Candida glabrata, Candida krusei and Candida guilliermondii with compounds 15-32, 15-15 and 15-1. The MIC for filamentous fungi was 1.95 μg·mL–1 for Aspergillus niger for compounds 15-1, 15-33 and 15-34. The results obtained support the use of NICS in the molecular design of compounds with antifungal activity.

Pyridine-substituted thiazolylphenol derivatives: Synthesis, modeling studies, aromatase inhibition, and antiproliferative activity evaluation

Ertas, Merve,Sahin, Zafer,Berk, Barkin,Yurttas, Leyla,Biltekin, Sevde N.,Demirayak, Seref

, (2018/03/21)

Drugs used in breast cancer treatments target the suppression of estrogen biosynthesis. During this suppression, the main goal is to inhibit the aromatase enzyme that is responsible for the cyclization and structuring of estrogens either with steroid or non-steroidal-type inhibitors. Non-steroidal derivatives generally have a planar aromatic structure attached to the triazole ring system in their structures, which inhibits hydroxylation reactions during aromatization by coordinating the heme group. Bioisosteric replacement of the triazole ring system and development of aromatic/cyclic structures of the side chain can increase the selectivity for aromatase enzyme inhibition. In this study, pyridine-substituted thiazolylphenol derivatives, which are non-steroidal triazole bioisosteres, were synthesized using the Hantzsch method, and physical analysis and structural determination studies were performed. The IC50 values of the compounds were determined by a fluorescence-based aromatase inhibition assay. Then, their antiproliferative activities on the MCF7 and HEK 293 cell lines were evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Furthermore, the crystal structure of human placental aromatase was subjected to a series of docking experiments to identify the possible interactions between the most active structure and the active site. Lastly, an in silico technique was performed to analyze and predict the drug-likeness, molecular and ADME properties of the synthesized molecules.

Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives

Sahin, Zafer,Ertas, Merve,Berk, Bark?n,Biltekin, Sevde Nur,Yurttas, Leyla,Demirayak, Seref

, p. 1986 - 1995 (2018/03/12)

Steroidal and non-steroidal aromatase inhibitors target the suppression of estrogen biosynthesis in the treatment of breast cancer. Researchers have increasingly focused on developing non-steroidal derivatives for their potential clinical use avoiding steroidal side-effects. Non-steroidal derivatives generally have planar aromatic structures attached to the azole ring system. One part of this ring system comprises functional groups that inhibit aromatization through the coordination of the haem group of the aromatase enzyme. Replacement of the triazole ring system and development of aromatic/cyclic structures of the side chain can increase selectivity over aromatase enzyme inhibition. In this study, 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives were synthesized and physical analyses and structural determination studies were performed. The IC50 values were determined by a fluorescence-based aromatase inhibition assay and compound 1 (4-(2-hydroxyphenyl)-2-(pyrimidine-2-yl)thiazole) were found potent inhibitor of enzyme (IC50:0.42 nM). Then, their antiproliferative activity over MCF-7 and HEK-293 cell lines was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Compounds 1, 7, 8, 13, 15, 18, 21 were active against MCF-7 breast cancer cells. Lastly, a series of docking experiments were undertaken to analyze the crystal structure of human placental aromatase and identify the possible interactions between the most active structure and the active site.

Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists

Nian, Si-Yun,Wang, Guo-Ping,Jiang, Zheng-Li,Xiao, Ying,Huang, Mo-Han,Zhou, Yi-Huan,Tan, Xiang-Duan

, p. 1 - 15 (2018/07/13)

Most of reported steroidal FXR antagonists are restricted due to low potency. We described the design and synthesis of novel nonsteroidal scaffold SIPI-7623 derivatives as FXR antagonists. The most potent compound A-11 (IC50 = 7.8 ± 1.1 μM) showed better activity compared to SIPI-7623 (IC50 = 40.8 ± 1.7 μM) and guggulsterone (IC50 = 45.9 ± 1.1 μM). Docking of A-11 in FXR’s ligand-binding domain was also studied.

Efficient synthesis of (R)-phenylephrine using a polymer-supported Corey-Bakshi-Shibata catalyst

Dai, Shuangxiong,Li, Guohua,Zhang, Wenbo,Zhang, Cuiyan,Song, Xiaoling,Huang, Di

, p. 740 - 743 (2017/05/16)

An efficient and mild synthetic route to (R)-phenylephrine hydrochloride using Corey-Bakshi-Shibata (CBS) catalyst was reported. In order to avoid a lengthy recovery process of the catalyst from homogeneous reaction, a polymer-supported CBS catalyst was prepared, and a preliminary attempt was made to achieve a continuous reduction on a laboratory scale, which contributes to synthesis of (R)-phenylephrine in a cost-effective way.

Citric Acid-catalyzed Synthesis of 2,4-Disubstituted Thiazoles from Ketones via C–Br, C–S, and C–N Bond Formations in One Pot: A Green Approach

Gundala, Trivikram Reddy,Godugu, Kumar,Nallagondu, Chinna Gangi Reddy

, p. 1408 - 1416 (2017/10/23)

An improved and greener protocol has been developed for the synthesis of 2,4-disubstituted thiazoles via C–Br, C–S, and, C–N bond formations in a single step from readily available ketones, N-bromosuccinimide (NBS), and thiourea catalyzed by citric acid in a mixture of ethanol and water (3:1) under reflux conditions. This method has the advantages of freedom from the isolation of lachrymatory α-bromoketones, ease of carrying out, cleaner reaction profile, broad substrate scope, freedom from chromatographic purification, and suitability for large-scale synthesis.

Highly Efficient Synthesis of α-Halomethylketones via Ce(SO4)2/Acid Co-Catalyzed Hydration of Alkynes

Zou, Huaxu,Jiang, Jun,Yi, Niannian,Fu, Wenqiang,Deng, Wei,Xiang, Jiannan

supporting information, p. 1251 - 1254 (2016/12/27)

A general atom-economical approach for the synthesis of α-halomethyl ketones is demonstrated through Ce(SO4)2/acid co-catalyzed hydration of a wide range of haloalkynes. The reactions are conducted under convenient conditions and provide products with excellent regioselectivity in good to excellent yields, with broad substrate scope. This protocol is an alternative to conventional α-halogenation of ketones.

In(OTf)3/acid co-catalyzed hydration of 1-haloalkynes to α-halomethyl ketones

Zeng, Ming,Huang, Rui-Xue,Li, Wen-Yi,Liu, Xiao-Wen,He, Fu-Ling,Zhang, Yi-Yuan,Xiao, Fang

, p. 3818 - 3822 (2016/07/06)

A novel and efficient In(OTf)3and HOAc cooperatively catalyzed hydration of 1-haloalkynes is described. This method provides ready access to α-chloromethyl ketones, α-bromomethyl ketones and α-iodomethyl ketones in moderate to high yields from simple, inexpensive starting materials. A broad substrate scope is achieved, and the reaction is compatible with various functional groups, including alkoxy, trifluoromethyl, halide, hydroxyl, cyclohexyl, and heterocyclic groups.

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis

Pesce, Emanuela,Bellotti, Marta,Liessi, Nara,Guariento, Sara,Damonte, Gianluca,Cichero, Elena,Galatini, Andrea,Salis, Annalisa,Gianotti, Ambra,Pedemonte, Nicoletta,Zegarra-Moran, Olga,Fossa, Paola,Galietta, Luis J.V.,Millo, Enrico

supporting information, p. 14 - 35 (2015/06/08)

Abstract The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gating) of CFTR protein. Other mutations, like G551D, only cause a gating defect. Processing and gating defects can be targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide indications about the chemical groups that are beneficial or detrimental for rescue activity. The new compounds were tested as correctors and potentiators in CFBE41o-expressing F508del-CFTR using a functional assay. A dual active compound, AAT-4a, characterized by improved efficacy and marked synergy when combined with the corrector VX-809 has been identified. Moreover, by computational methods, a possible binding site for AATs in nucleotide binding domain NBD1 has been detected. These results will direct the synthesis of new analogues with possibly improved activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2491-37-4